配对尿路上皮与鳞状膀胱癌的靶向DNA和RNA测序揭示不一致的基因组与转录组事件及独特治疗意义
该研究对112例FFPE膀胱癌样本(含12对尿路上皮/鳞状成分)和21个细胞系进行靶向DNA/RNA测序,评估组织学异质性对表达亚型的影响。发现12对中有3对(25%)的尿路上皮与鳞状成分呈现不同的基底/管腔亚型,尽管其优先体细胞基因组改变相同,提示表达亚型在组织学异质性肿瘤中需谨慎解读。
要点
- 配对尿路上皮与鳞状成分在25%(3/12)病例中显示不一致的基底/管腔亚型。
- 尽管基因组改变相同,表达亚型可因组织学成分而异。
- 靶向RNA测序可用于临床样本的亚型评估。
核心结论
- 表达亚型在组织学异质性膀胱癌中可能不一致,应谨慎解读。
研究设计与样本
- 对112例FFPE膀胱癌样本(包括12例配对尿路上皮/鳞状成分)和21个膀胱癌细胞系进行靶向DNA和/或RNA测序(mxDNAseq和mxRNAseq)。
主要发现
- 在21个细胞系中,mxRNAseq与全转录组测序高度一致。
- 69例高质量组织样本中常见TP53有害突变(56%)和PIK3CA激活热点突变(30%)。
- 发现潜在可靶向的ERBB2(6%)或EGFR(6%)局灶扩增。
- 12对配对尿路上皮和鳞状成分中,3对(25%)显示不同的基底/管腔状态,尽管优先体细胞基因组改变相同。
关键数值与推荐
- 12对配对样本中3对(25%)显示基底/管腔亚型不一致。
- TP53有害突变频率56%,PIK3CA激活突变频率30%,ERBB2扩增6%,EGFR扩增6%(69例高质量组织样本)。
临床怎么用
- 对于组织学异质性膀胱癌,基于表达亚型的解读需谨慎,可能需要多区域检测。
局限性
- 缺乏配对正常组织用于正式体细胞改变判定。
- 需要正式的分析和临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrated molecular profiling has identified intrinsic expression-based bladder cancer molecular subtypes. Despite frequent histological diversity, robustness of subtypes in paired conventional (urothelial) and squamous components of the same bladder tumor has not been reported. OBJECTIVE: To assess the impact of histological heterogeneity on expression-based bladder cancer subtypes. DESIGN, SETTING, AND PARTICIPANTS: We performed clinically applicable, targeted DNA and/or RNA sequencing (multiplexed DNA and RNA sequencing [mxDNAseq and mxRNAseq, respectively]) on 112 formalin-fixed paraffin-embedded (FFPE) bladder cancer samples, including 12 cases with paired urothelial/squamous components and 21 bladder cancer cell lines. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Unsupervised hierarchical and consensus clustering of target gene expression enabled derivation of basal/luminal molecular subtyping. RESULTS AND LIMITATION: Across 21 bladder cancer cell lines, our custom mxRNAseq panel was highly concordant with whole transcriptome sequencing, and assessed targets robustly determined expression-based basal/luminal subtypes from The Cancer Genome Atlas data (in silico) and internally sequenced FFPE tissues. Frequent deleterious TP53 (56%) and activating hotspot PIK3CA (30%) somatic mutations were seen across 69 high-quality tissue samples. Potentially targetable focal ERBB2 (6%) or EGFR (6%) amplifications were also identified, and a novel subgene copy-number detection approach is described. Combined DNA/RNA analysis showed that focally amplified samples exhibit outlier EGFR and ERBB2 expression distinct from subtype-intrinsic profiles. Critically, paired urothelial and squamous components showed divergent basal/luminal status in three of 12 cases (25%), despite identical putatively clonal prioritized somatic genomic alterations. Limitations include lack of profiled paired normal tissues for formal somatic alteration determination, and the need for formal analytical and clinical validation. CONCLUSIONS: Our results support the feasibility of clinically relevant integrative bladder cancer profiling and challenge the intrinsic nature of expression subtypes in histologically diverse bladder cancers. PATIENT SUMMARY: A targeted RNA sequencing assay is capable of assessing gene expression-based subtypes in individual components of clinical bladder cancer tissue specimens. Different histological components of the same tumor may yield divergent expression profiles, suggesting that expression-based subtypes should be interpreted with caution in heterogeneous cancers.
引用
- Hovelson DH, Udager AM, McDaniel AS, et al. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. Eur Urol. 2018. PMID: 30033047. doi:10.1016/j.eururo.2018.06.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。